Of the diabetic subjects with CAD 30.8% was on treatment with sulphonylurea, 59.8% on metformin, 3.7% on glitazones, 3.7% on acarbose, 2.8% on megltitinides, 8.4% on DPP-4 inhibitors, and 51.5% on insulin. The gene discussed is DPP4; the disease is coronary artery disorder.